Ishii Shirou, Kikuchi Ken, Miyajima Masayuki, Sakuma Kotaro, Shishido Fumio
Fukushima J Med Sci. 2015;61(1):23-31. doi: 10.5387/fms.2013-15. Epub 2015 May 3.
To validate the use of bone scintigraphy (BS) versus computed tomography (CT) for therapeutic monitoring in patients during treatment with zoledronic acid.
Eleven patients with bone-only metastatic disease and being treated with zoledronic acid were included. The effects of therapies including chemotherapy and hormone therapy were evaluated in 25 separate examinations in total as follows: complete response (CR), when no bone metastasis was visible; partial response (PR), when a decrease in the lesion area was detected; stable disease (SD), when no or slight change was observed; and progressive disease (PD), when new or enlarged lesion areas were observed.
The accuracies of examination by Readers 1, 2, and 3 respectively were 76%, 80% and 76% for BS, 52%, 48%, and 40% for CT, and 64%, 52% and 60% for BS and CT combined with Readers 2 and 3 observing significant differences between CT and BS results. The rates of interobserver agreement between Readers 1 and 2, between Readers 1 and 3, and between Reader 2 and 3 respectively, were 84%, 80% and 88% (κ = 0.648, 0.561 and 0.766) for BS, 52%, 56%, and 60% (κ = 0.180, 0.278 and 0.282) for CT, and 52%, 60%, and 56% (κ = 0.215, 0.282 and 0.232) for CT and BS combined.
BS is effective for assessing the response of bone metastasis to therapy in patients during zoledronic acid treatment.
验证骨闪烁显像(BS)与计算机断层扫描(CT)在唑来膦酸治疗患者中用于治疗监测的效果。
纳入11例仅患有骨转移疾病且正在接受唑来膦酸治疗的患者。总共在25次单独检查中评估了包括化疗和激素治疗在内的治疗效果,具体如下:完全缓解(CR),即未见骨转移;部分缓解(PR),即检测到病变面积减小;疾病稳定(SD),即未见变化或仅有轻微变化;疾病进展(PD),即观察到新的或扩大的病变区域。
读者1、读者2和读者3进行检查的准确率,BS分别为76%、80%和76%,CT分别为52%、48%和40%,BS与CT联合时分别为64%、52%和60%,读者2和读者3观察到CT与BS结果之间存在显著差异。读者1与读者2之间、读者1与读者3之间以及读者2与读者3之间的观察者间一致性率,BS分别为84%、80%和88%(κ = 0.648、0.561和0.766),CT分别为52%、56%和60%(κ = 0.180、0.278和0.282),CT与BS联合时分别为52%、60%和56%(κ = 0.215、0.282和0.232)。
BS在评估唑来膦酸治疗期间患者骨转移对治疗的反应方面是有效的。